MedTrace Logo

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06703021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2026-04-28

No results posted yet for this study

Summary

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.

Conditions

Interventions

DRUG

aleniglipron or placebo

Drug: aleniglipron administered orally; Drug: placebo administered orally

DRUG

aleniglipron or placebo

Drug: aleniglipron administered orally; Drug: placebo administered orally

DRUG

aleniglipron or placebo

Drug: aleniglipron administered orally; Drug: placebo administered orally

DRUG

aleniglipron or placebo

Drug: aleniglipron administered orally; Drug: placebo administered orally

Sponsors & Collaborators

  • Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-20
Primary Completion
2026-01-12
Completion
2026-01-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06703021 on ClinicalTrials.gov